6.1.3 Both males and females may be enrolled. All patients should be 
counselled regarding the need for effective contraception because of the 
possible teratogenic/mutagenic effect of the rIL-2. Premenopausal females 
must have a negative pregnancy test prior to surgery and within one week 
of treatment. 
6.1.4 Patients must be ambulatory with a Kamofsky Performance status greater 
than or equal to 70 percent have a life expectancy of greater than 16 
weeks. 
6.1.5 Patients must have the following minimum values:BC > 3500/MM 3 , 
Hgn>10 gm/dl; platelets > 100,000/mm 3 ; granulocytes 
> 1500/mm 3 ; serum creatinine <2.0 mg/dl; bilirubin <1.5 mg/dl;SGOT 
< 150IU/L or 4 x upper limit; PTT < 1.5 x control. 
6.1.6 Patients must have a Cardiac status of 1 (one) on the modified New York 
Heart Association scale (Appendix VI,) with no evidence of congestive 
heart failure or coronary artery disease; no serious cardiac arrhythmias or 
evidence of prior myocardial infarction. 
6.1.7 No evidence of active opportunistic infection. 
6.1.8 A minimum of 4 weeks must have elapsed since the completion of prior 
radiotherapy. No concurrent radiotherapy or chemotherapy is permitted. 
6.1.9 A minimum of 8 weeks must have elapsed since the completion of 
previous immunotherapy, including IL-2 therapy. 
6.1.10 The patient must give informed consent. 
6.2 EXCLUSION CRITERIA 
6.2.1 Patients with organ allografts 
6.2.2 Patients who require or are likely to require corticocosteroids for 
intercurrent disease. 
6.2.3 Patients with a history of malignant disease, excluding basal cell 
carcinoma, or infection with the human immunodeficiency virus (HIV). 
6.2.4 Patients with any major psychiatric illness, unstable blood pressure, known 
CNS or seizure disorders, severe diabetes, or active infection. 
Recombinant DNA Research, Volume 15 
[525] 
